Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Egbert F Smit

Showing results (161-170 of 367) with videos related to

Pageof 37
Sort By:
Plos One|May 30, 2013
Pemetrexed induced thymidylate synthase inhibition in non-small cell lung cancer patients: a pilot study with 3'-deoxy-3'-[¹⁸F]fluorothymidine positron emission tomographyVirginie Frings, Astrid A M van der Veldt, Ronald Boellaard, et al.
Acta Oncologica (Stockholm, Sweden)|August 21, 2013
Changes in non-surgical management of stage III non-small cell lung cancer at a single institution between 2003 and 2010Ellen J F van Reij, Max Dahele, Peter M van de Ven, et al.
International Journal of Molecular Sciences|January 8, 2023
Detection of Circulating Tumor Cells Using the Attune NxTMandy Gruijs, Carolien Zeelen, Tessa Hellingman, et al.
Cell Reports|May 7, 2020
Challenges in Establishing Pure Lung Cancer Organoids Limit Their Utility for Personalized MedicineKrijn K Dijkstra, Kim Monkhorst, Luuk J Schipper, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2003
Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group--EORTC 08975Egbert F Smit, Jan P A M van Meerbeeck, Pilar Lianes, et al.
ERJ Open Research|December 21, 2019
Tumour growth rate as a tool for response evaluation during PD-1 treatment for non-small cell lung cancer: a retrospective analysisDeirdre M H J Ten Berge, Daniel P Hurkmans, Ilse den Besten, et al.
Clinical Pharmacology and Therapeutics|July 21, 2020
Exposure-Response Analyses of Anaplastic Lymphoma Kinase Inhibitors Crizotinib and Alectinib in Non-Small Cell Lung Cancer PatientsStefanie L Groenland, Dieuwertje R Geel, Julie M Janssen, et al.
Eupa Open Proteomics|June 15, 2018
Peptide-mediated 'miniprep' isolation of extracellular vesicles is suitable for high-throughput proteomicsJaco C Knol, Inge de Reus, Tim Schelfhorst, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 18, 2012
Negative NKX2-1 (TTF-1) as temporary surrogate marker for treatment selection during EGFR-mutation analysis in patients with non-small-cell lung cancerJulien Vincenten, Egbert F Smit, Wim Vos, et al.
European Journal of Cancer (Oxford, England : 1990)|September 11, 2007
Phase III study of cyclophosphamide, doxorubicin, and etoposide compared with carboplatin and paclitaxel in patients with extensive disease small-cell lung cancerWouter K de Jong, Harry J M Groen, Mia G J Koolen, et al.
Pageof 37

Showing results (161-170 of 367) with videos related to

Sort By:
Pageof 37
Plos One|May 30, 2013
Pemetrexed induced thymidylate synthase inhibition in non-small cell lung cancer patients: a pilot study with 3'-deoxy-3'-[¹⁸F]fluorothymidine positron emission tomographyVirginie Frings, Astrid A M van der Veldt, Ronald Boellaard, et al.
Acta Oncologica (Stockholm, Sweden)|August 21, 2013
Changes in non-surgical management of stage III non-small cell lung cancer at a single institution between 2003 and 2010Ellen J F van Reij, Max Dahele, Peter M van de Ven, et al.
International Journal of Molecular Sciences|January 8, 2023
Detection of Circulating Tumor Cells Using the Attune NxTMandy Gruijs, Carolien Zeelen, Tessa Hellingman, et al.
Cell Reports|May 7, 2020
Challenges in Establishing Pure Lung Cancer Organoids Limit Their Utility for Personalized MedicineKrijn K Dijkstra, Kim Monkhorst, Luuk J Schipper, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2003
Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group--EORTC 08975Egbert F Smit, Jan P A M van Meerbeeck, Pilar Lianes, et al.
ERJ Open Research|December 21, 2019
Tumour growth rate as a tool for response evaluation during PD-1 treatment for non-small cell lung cancer: a retrospective analysisDeirdre M H J Ten Berge, Daniel P Hurkmans, Ilse den Besten, et al.
Clinical Pharmacology and Therapeutics|July 21, 2020
Exposure-Response Analyses of Anaplastic Lymphoma Kinase Inhibitors Crizotinib and Alectinib in Non-Small Cell Lung Cancer PatientsStefanie L Groenland, Dieuwertje R Geel, Julie M Janssen, et al.
Eupa Open Proteomics|June 15, 2018
Peptide-mediated 'miniprep' isolation of extracellular vesicles is suitable for high-throughput proteomicsJaco C Knol, Inge de Reus, Tim Schelfhorst, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 18, 2012
Negative NKX2-1 (TTF-1) as temporary surrogate marker for treatment selection during EGFR-mutation analysis in patients with non-small-cell lung cancerJulien Vincenten, Egbert F Smit, Wim Vos, et al.
European Journal of Cancer (Oxford, England : 1990)|September 11, 2007
Phase III study of cyclophosphamide, doxorubicin, and etoposide compared with carboplatin and paclitaxel in patients with extensive disease small-cell lung cancerWouter K de Jong, Harry J M Groen, Mia G J Koolen, et al.
Pageof 37